This vascular running phenomenon represents a unique therapeutic approach
structure-activity relationships of -MSH C-terminal pharmacophore Systemic (Preclinical) Murine models of crystal-induced peritonitis
MAFLD is defined as hepatic steatosis with metabolic dysregulation, type 2 diabetes mellitus, overweight or obesity, and is characterized by extensive liver lesions, which can progress from isolated steatosis to metabolic dysfunction-associated steatohepatitis (MASH), liver fibrosis, and even HCC
These include N,N -bis(2-hydroxybenzyl)ethylenediamine- N,N -diacetic acid (HBED), the hydrazones pyridoxal isonicotinoyl hydrazone (PIH) and salicylaldehyde isonicotinoyl hydrazone (SIH), desferrithiocin, and, 2,3-dihydrobenzoic acid